128 related articles for article (PubMed ID: 30877365)
1. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
3. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
5. Relevance of
Zhong L; Fu Q; Zhou S; Chen L; Peng Q
BMJ Open; 2018 May; 8(5):e020767. PubMed ID: 29804062
[TBL] [Abstract][Full Text] [Related]
6. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
9. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
[TBL] [Abstract][Full Text] [Related]
10. Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta-analysis.
Chen XL; Wang YM; Zhao F; Chen Z; Yang X; Sun C; Gao Y; Yang TG; Tian G; Chen YM; Zhu SL; Lin XB; Liu FB
J Gene Med; 2019 Sep; 21(9):e3114. PubMed ID: 31330573
[TBL] [Abstract][Full Text] [Related]
11. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
12. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
13. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
14. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
[TBL] [Abstract][Full Text] [Related]
15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
16. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
[TBL] [Abstract][Full Text] [Related]
17. Allele and Genotype Frequencies of the Polymorphic Methylenetetrahydrofolate Reductase and Lung Cancer in ther Jordanian Population: a Case Control Study.
Al-Motassem Y; Shomaf M; Said I; Berger S; Ababneh N; Diab O; Obeidat N; Awidi A
Asian Pac J Cancer Prev; 2015; 16(8):3101-9. PubMed ID: 25921104
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
[TBL] [Abstract][Full Text] [Related]
19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]